VELTASSA 16.8 G — DIN 02481367
PATIROMER (PATIROMER SORBITEX CALCIUM) : 16.8 G · VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD · POWDER FOR SUSPENSION · wholesale supply in Canada
Health Canada status: MARKETED
What is VELTASSA?
VELTASSA 16.8 G contains PATIROMER (PATIROMER SORBITEX CALCIUM) : 16.8 G. It is listed in the Health Canada Drug Product Database under DIN 02481367, held by VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD, supplied as POWDER FOR SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 27-Nov-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VELTASSA used for?
Treatment of hyperkalemia in adults with chronic kidney disease (eGFR ≥15mL/min/1.73m2). Not for emergency treatment of life-threatening hyperkalemia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Patiromer Calcium cost around the world?
Patiromer Calcium is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Italy publishes a prezzo al pubblico (classe A). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 1 | 4 | AUD███.██ |
| Italy | prezzo al pubblico (classe A) | 2 | 2 | EUR███.██ |
6 pack listings across 3 brand entries and 2 price bases, refreshed 08 Sep 2026. Ranges span every Patiromer Calcium pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Patiromer Calcium in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Patiromer Calcium — 3 DINs, of which 2 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD | 3 | 2 | VELTASSA | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 16.8 G |
|---|---|
| Dosage form | POWDER FOR SUSPENSION |
| Route | ORAL |
| Pack configuration (monograph) | Sachets of 8.4 g, 16.8 g, and 25.2 g. Supplied in boxes of 30 sachets (8.4 g also available in boxes of 4). |
| Storage | Not explicitly detailed in provided text (refer to full monograph), but must not be heated or added to hot foods/liquids. Mixture must be taken within 1 hour of reconstitution. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Patiromer Calcium |
|---|---|
| ATC code | V03AE09 |
| AHFS class | 40:18.18 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02481367 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2481367 |
| Brand name | VELTASSA |
| Generic / active ingredient | PATIROMER (PATIROMER SORBITEX CALCIUM) : 16.8 G |
| Market authorization holder | VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD |
| Health Canada schedule | Prescription |
| ATC code | V03AE09 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V03AE |
| Current status | MARKETED |
| Status date | 27-Nov-2019 |
| Original market date | 2019-11-27 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Recommended starting dose is 8.4 g once daily. Adjust dose in intervals of one week or longer based on serum potassium. Maximum dose 25.2 g once daily. Separate from other oral drugs by 3 hours.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to this drug or any ingredient; patients with the rare hereditary condition of fructose intolerance (contains sorbitol).
Warnings and precautions
Delayed onset (4-7 hours). Risk of hypokalemia and hypomagnesemia. Use caution in patients with severe GI disorders (risk of ischemia/perforation). Monitor serum potassium and magnesium.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| VELTASSA | 8.4 G | POWDER FOR SUSPENSION | VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD | MARKETED | 02481359 |
| VELTASSA | 25.2 G | POWDER FOR SUSPENSION | VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD | APPROVED | 02481375 |
2 · Same class — other molecules in ATC V03AE
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Polystyrene Sulphonate | JAMP CALCIUM POLYSTYRENE SULFONATE · JAMP SODIUM POLYSTYRENE SULFONATE · K-EXIT POUDRE · KAYEXALATE · +8 more | 16 | 7 | Yes |
| Lanthanum Carbonate | FOSRENOL · NAT-LANTHANUM | 8 | 4 | Yes |
| Sevelamer | ACCEL-SEVELAMER · INTELLI-SEVELAMER · RENAGEL · RENVELA | 8 | 3 | Yes |
| Patiromer Calcium | VELTASSA | 3 | 2 | Yes |
| Sodium Zirconium Cyclosilicate | LOKELMA | 2 | 2 | Yes |
| Sucroferric Oxyhydroxide | VELPHORO | 1 | 1 | Yes |
| Drugs For Treatment Of Hyperkalemia And Hyperphosphatemia | PHOSLO TABLETS | 1 | 0 | Not in Canada |
| Calcium Acetate | CALCIUM ACETATE TAB 667MG | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC V03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| V03AC | Deferasirox · Deferiprone · Deferoxamine | 57 | 44 |
| V03AN | Carbon Dioxide · Combination · Helium · Medical Air · Medical Gases · +2 more | 112 | 43 |
| V03AB | Amyl Nitrite · Andexanet Alfa · Antidotes · Digitalis Antitoxin · Dimercaprol · +16 more | 87 | 31 |
| V03AF | Amifostine · Calcium Folinate · Dexrazoxane · Mesna · Palifermin · +1 more | 34 | 16 |
| V03AH | Diazoxide | 2 | 1 |
| V03AX | Cobicistat · Difelikefalin · Other Therapeutic Products | 8 | 1 |
| V03AZ | Ethanol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.